Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2019 on request of the sponsor.

On 21 October 2004, orphan designation (EU/3/04/229) was granted by the European Commission to BioAlliance Pharma, France, for doxorubicin polyisohexylcyanoacrylate nanoparticles for the treatment of hepatocellular carcinoma.

In October 2014, BioAlliance Pharma changed name to Onxeo.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Doxorubicine polyisohexylcyanoacrylate nanoparticles
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

49, Bd Gal Martial Valin
F-75015 Paris
Tel. +33 1 45 58 76 00
Fax +33 1 45 58 08 81

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating